3rd Quarter 2012 Commentary - ASTON/Veredus Select Growth Fund
3rd Quarter 2012
Despite a solid rally that began in late July, mostly on the heels of comments from the president of the European Central Bank (ECB) that the bank would provide whatever liquidity needed to save the EU, many investors remain fixated on the macroeconomic problems in Europe, the looming “fiscal cliff” here in the U.S., and the upcoming U.S. elections. Although the market has shown remarkable resiliency, the problems facing global economies are very real. The market is a tremendous discounting mechanism that we think is coming around to the fact that with government spending beyond its means and the Federal Reserve largely out of monetary “bullets”, we are now in desperate need for fiscal reform to fix the damage that both parties in Congress have heaped on the American people and its economic system.
What would this mean for markets? More certainty about taxes, regulations and spending that could translate into multiple expansion for equities. We think it would lower correlations between stocks and dramatically reduce the market’s dependency on macroeconomic events, allowing for more emphasis on company fundamentals. Until that happens, however, markets are likely to continue to be driven by volatile macroeconomic events.
The Fund underperformed its Russell 1000 Growth Index benchmark during the quarter. There were two primary areas of weakness—Healthcare and Industrials—with most of the relative underperformance occurring in July. The portfolio came back nicely in August and September, but not enough to overcome the deficit from the opening month of the quarter. United Airlines and BE Aerospace were the problem names within Industrials, and are no longer held by the Fund.
Worries over utilization rates affected Healthcare holdings such as HCA, Zimmer, and Intuitive Surgical, but it was Questcor Pharmaceuticals that hurt returns the most. A specialty pharmaceutical company, Questcor suffered from rumors that generic competition from a European compound might threaten the position of its Achtar drug, used as the last line of defense in some debilitating diseases. We trimmed back on the portfolio’s sizeable stake in the face of this news, and then sold the position immediately when a major health insurer decided not to reimburse for the treatment, limiting further losses.
Holdings in Consumer Discretionary, Technology, and Financials outperformed the index during the quarter. Consumer Discretionary exposure was the standout led by retailers LuLu Lemon and Michael Kors, and homebuilders Lennar and DR Horton. Homebuilders surged on positive data from the housing market, including five-year lows for inventories and foreclosures. Despite a slight underweighting in the area, holdings in Apple, eBay, Google, and Accenture boosted returns in Technology.
As the market digests its move off the bottom from the correction of late spring and early summer, we truly believe that the “pain trade” is to the upside as lagging hedge funds feel compelled to play catch up. Thus, we think managers will run after stocks that have worked thus far, namely in the Consumer, Healthcare, and Financials sectors.
Charles F. Mercer, Jr. CFA B. Anthony Weber Michael E. Johnson, CFA
October 12, 2012
As of September 30, 2012, HCA Holdings comprised 2.73% of the portfolio's assets, Zimmer – 0.00%, Intuitive Surgical – 0.00%, LuLu Lemon – 0.00%, Michael Kors – 4.23%, Lennar – 0.00%, DR Horton – 0.00%, Apple – 5.65%, eBay – 4.93%, Google – 3.56%, and Accenture – 1.82%.
Note: Growth stocks are generally more sensitive to market moves and thus may be more volatile than other stocks.
Before investing, consider the Fund’s investment objectives, risks, charges, and expenses. Contact 800 992-8151 for a prospectus or summary prospectus containing this and other information. Please, read it carefully. Aston Funds are distributed by Foreside Funds Distributors LLC.